BEL secures manufacturing licence for indigenous RxT17 Hemodialysis machine

Bharat Electronics Limited (BEL) has secured the licence to manufacture and sell its indigenously developed hemodialysis machine, BEL RxT17
Alt="RxT17 Hemodialysis machine"
BEL secures manufacturing licence for indigenous RxT17 Hemodialysis machineRxT17 Hemodialysis machine
Published on

New Delhi: Bharat Electronics Limited (BEL) has secured the licence to manufacture and sell its indigenously developed hemodialysis machine, BEL RxT17, marking a significant step in India’s growing medical technology capabilities.

Follow The PSUWatch Channel on WhatsApp

The licence has been granted by the Central Drugs Standard Control Organisation (CDSCO) following successful compliance with Class C regulatory requirements, which pertain to high-risk medical devices and stringent safety and performance standards.

Developed in collaboration with Renalyx and to be manufactured by BEL, the RxT17 is among the first indigenous hemodialysis machines in India. The development is expected to benefit patients suffering from chronic kidney conditions by enabling safe, efficient and high-quality dialysis therapy.

The BEL RxT17 is CE certified, indicating compliance with European safety, health and environmental standards, and facilitating its acceptance in global markets. The device comes equipped with a colour touchscreen interface that provides real-time information on operational parameters, along with integrated audio and visual alarms for critical conditions.

Designed for compatibility with standard consumables and disposables, the machine ensures seamless integration into existing hospital workflows. Its simplified design also focuses on ease of operation and maintenance for healthcare providers.

Follow PSU Watch on LinkedIN

Alt="RxT17 Hemodialysis machine"
BEL clocks record Rs 26,750 crore turnover in FY26, exports rise over 33%

With the rising incidence of End-Stage Renal Disease in India, demand for dialysis services has been increasing steadily. BEL said the RxT17 aims to enhance accessibility and affordability of dialysis care across the country.

The development is also expected to reduce India’s dependence on imported dialysis equipment and strengthen the domestic medtech manufacturing ecosystem. It aligns with the government’s ‘Aatmanirbhar Bharat’ initiative to promote indigenous, high-quality and globally competitive medical technologies.

(PSU Watch– India's Business News centre that places the spotlight on PSUs, Bureaucracy, Defence and Public Policy is now on Google News. Click here to follow. Also, join PSU Watch Channel in your Telegram. You may also follow us on Twitter here and stay updated.)

logo
PSU Watch
psuwatch.com